TPC
THRD

Takeda Pharmaceutical Company’s Third Harmonic Bio THRD Stock Holding History

Takeda Pharmaceutical Company’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,835
Closed -$200K – 10
2025
Q2 		$200K Hold
36,835
– – 1.02% 9
2025
Q1 		$128K Hold
36,835
– – 0.79% 10
2024
Q4 		$379K Buy
+36,835
New +$459K 1.43% 9

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Takeda Pharmaceutical Company's THRD Position: Q3 2025 in Review

Takeda Pharmaceutical Company sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 36,835 shares — an estimated $200K sold.

Takeda Pharmaceutical Company first reported a position in THRD in Q4 2024 and held it in 3 quarters. The position peaked at $379K in Q4 2024. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Takeda Pharmaceutical Company reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Takeda Pharmaceutical Company sold 36,835 Third Harmonic Bio shares in Q3 2025, an estimated $200K.
  • Takeda Pharmaceutical Company first reported a position in Third Harmonic Bio in Q4 2024 and held it in 3 quarters.
  • Takeda Pharmaceutical Company's Third Harmonic Bio position peaked at $379K in Q4 2024.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.